Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183317 | 0.96 | ATM (0.40) | ATMALDH1A1MAPK1HTR2AHTR2C | |
| SCHEMBL4185689 | 0.93 | ATM (0.42) | ATMALDH1A1HTR2AHTR2CRAB9A | |
| SCHEMBL4191772 | 0.92 | ATM (0.40) | ATMALDH1A1MAPK1HTR2AHTR2C | |
| SCHEMBL4190119 | 0.92 | ATM (0.40) | ATMALDH1A1MAPK1HTR2AHTR2C | |
| SCHEMBL4188236 | 0.91 | CTSS (0.40) | ATMALDH1A1MAPK1HTR2AHTR2C | |
| SCHEMBL4183323 | 0.89 | TSHR (0.44) | ATMALDH1A1MAPK1HTR2AHTR2C | |
| SCHEMBL4179151 | 0.89 | ALDH1A1 (0.41) | ATMALDH1A1MAPK1HTR2AHTR2C | |
| SCHEMBL4179150 | 0.89 | ALDH1A1 (0.41) | ATMALDH1A1MAPK1HTR2AHTR2C | |
| SCHEMBL4185277 | 0.88 | ATM (0.41) | ATMALDH1A1MAPK1HTR2AHTR2C | |
| SCHEMBL5487435 | 0.85 | CTSL (0.40) | ATMMAPK1RAB9AKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | claimed |
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | TRPV4, TRPC4, TRPV1 | ATM 4685/4885ALDH1A1 961/4885MAPK1 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.